Core and Group Health

H.R. 3 would direct Medicare to set pharmaceutical prices based on an index of what other developed nations pay for top-selling drugs.

The judge overseeing a lawsuit delayed the trial over concerns too many jurors have already bowed out.

Implementation of Medicaid work requirements are costing states hundreds of millions of dollars.

A new report examines seven drugs "for which there was no new clinical evidence that could support their price increases."

Well-being programs can absolutely succeed, but standardized approaches will not have long-lasting, positive impacts.

How much can Medicare pricing data and working with carriers to narrow networks bring down health costs for employers?